I agree that this site is using cookies. You can find further informations here.
X
Jhaveri, Komal L.
75  results:
OpenAccess-fulltext X
Search for persons X
?
1

Neratinib + fulvestrant + trastuzumab for HR-positive, HER2..:

Jhaveri, Komal L ; Eli, Lisa Diamond ; Wildiers, Hans P.M.W...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.annonc.2023.08.003.  , 2023
Link: https://hal.science/hal-..
 
?
2

Neratinib + fulvestrant + trastuzumab for HR-positive, HER2..:

Jhaveri, Komal L ; Eli, Lisa Diamond ; Wildiers, Hans P.M.W...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.annonc.2023.08.003.  , 2023
Link: https://hal.science/hal-..
 
?
3

Quality of life with ribociclib versus abemaciclib as first..:

Rugo, Hope S ; Harmer, Victoria ; O'Shaughnessy, Joyce...
qt7qf8665q.  , 2023
Link: https://escholarship.org..
 
?
4

Neratinib + fulvestrant + trastuzumab for HR-positive, HER2..:

Jhaveri, Komal L ; Eli, Lisa Diamond ; Wildiers, Hans P.M.W...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.annonc.2023.08.003.  , 2023
Link: https://hal.science/hal-..
 
?
5

TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in..:

Bardia, Aditya ; Jhaveri, Komal ; Kalinsky, Kevin...
Future Oncology.  , 2023
Link: https://hdl.handle.net/1..
 
?
6

Quality of life with ribociclib versus abemaciclib as first..:

Rugo, Hope S ; Harmer, Victoria ; O'Shaughnessy, Joyce...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9969464/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
7

Antitumour activity of neratinib in patients with HER2-muta..:

Harding, James J ; Piha-Paul, Sarina A ; Shah, Ronak H...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902444/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
8

Quality of life with ribociclib versus abemaciclib as first..:

Rugo, Hope S ; Harmer, Victoria ; O'Shaughnessy, Joyce...
https://opus4.kobv.de/opus4-fau/frontdoor/index/index/docId/21759.  , 2023
Link: https://opus4.kobv.de/op..
 
?
9

Serial monitoring of genomic alterations in circulating tum..:

Cani, Andi K ; Dolce, Emily M ; Darga, Elizabeth P...
Molecular Oncology, Vol.16 No.10, pp.1969-1985.  , 2022
Link: https://hdl.handle.net/1..
 
?
10

The oral selective estrogen receptor degrader GDC-0810 (ARN..:

Bardia, Aditya ; Mayer, Ingrid ; Winer, Eric...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9823088/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
11

Abemaciclib in Combination With Endocrine Therapy for Patie..:

Tolaney, Sara M ; Beeram, Muralidhar ; Beck, J. Thaddeus...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8868006/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
12

The oncogenic PI3K-induced transcriptomic landscape reveals..:

Ladewig, Erik ; Michelini, Flavia ; Jhaveri, Komal...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354703/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
13

Characterization, management, and risk factors of hyperglyc..:

Liu, Dazhi ; Weintraub, Michael A ; Garcia, Christine...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9041081/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
14

Head-to-Head Evaluation of (18)F-FES and (18)F-FDG PET/CT i..:

Ulaner, Gary A ; Jhaveri, Komal ; Chandarlapaty, Sarat...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8049349/.  , 2021
Link: http://www.ncbi.nlm.nih...
 
?
15

Genomic alterations in PIK3CA-mutated breast cancer result ..:

Cai, Yanyan ; Xu, Guotai ; Wu, Fan...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137641/.  , 2021
Link: http://www.ncbi.nlm.nih...
 
1-15